Angiotech receives letter from TSX to delist its common shares on March 3, 2011

Angiotech Pharmaceuticals, Inc. today announced that on February 1, 2011, Angiotech received a letter from the Toronto Stock Exchange stating that Angiotech's common shares will be delisted from the TSX effective at the close of market on March 3, 2011.  The delisting was imposed as a result of the Company not meeting the continued listing requirements of the TSX.  As announced previously, the TSX suspended trading in the Company's common shares effective at January 28, 2011.  Trading in the Company's common shares will remain suspended until the time of delisting.  Angiotech does not intend to appeal the TSX's decision to delist its common shares. Therefore, trading in Angiotech's common shares will be scheduled for delisting from the TSX at the close of market on March 3, 2011.

Source: ANGIOTECH PHARMACEUTICALS, INC